BiotechTubeBiotechTube
Home/MeiraGTx/Natalie Mount, Ph.D.
NM

Natalie Mount, Ph.D.

Executive Vice President, Program & Portfolio Management

MeiraGTx

Therapeutic Areas

OphthalmologyNeurologyRare Diseases

MeiraGTx Pipeline

DrugIndicationPhase
botaretigene sparoparvovec (bota-vec, AAV-RPGR)X-linked retinitis pigmentosa (XLRP)Phase 3
AAV-CNGB3Achromatopsia (CNGB3-associated)Phase 1/2
AAV-CNGA3Achromatopsia (CNGA3-associated)Phase 1/2
AAV-AQP1Radiation-induced xerostomiaPhase 1
AAV-GADParkinson's DiseasePreclinical/Phase 1
AAV-UPF1Amyotrophic Lateral Sclerosis (ALS)Preclinical

Leadership Team at MeiraGTx

AF
Alexandria Forbes, Ph.D.
President, Chief Executive Officer, and Director
RG
Richard Giroux
Chief Operating Officer and Chief Financial Officer
MS
M. Scott Salka
Chief Business Officer
MD
Michele DiMascio, Ph.D.
Senior Vice President, Head of Manufacturing
JW
John W. Smither
Senior Vice President, Chief Financial Officer (former)
ZF
Zandy Forbes, Ph.D.
Founder and Director
PF
Patrick F. Terry
Director
RJ
Robert J. (Bob) Iannone, M.D., M.S.C.E.
Director (Executive Vice President, Head of R&D, Janssen)
J(
James (Jay) M. Wilson, Ph.D.
Director (Scientific Founder)
GR
Gregory Robinson
Director
View full MeiraGTx profile